BCAA has been shown to positively affect sarcopenia, which is an independent risk factor for hepatic encephalopathy itself 57
7 Future perspectives Despite the promising potential of GLP-1RAs for the treatment of AF by targeting EAT, numerous significant challenges remain for their clinical translation
In practice, a higher dose may be considered if: You have already reached 2.4 mg and need additional weight loss You tolerate the medication without significant gastrointestinal side effects Your healthcare provider determines that further dose escalation is appropriate based on your clinical response The decision to move toward the highest dose of Wegovy for weight loss is individualized and based on both effectiveness and tolerability, rather than being routinely required for all patients
These differences support a potentially complementary therapeutic strategy in patients with overlapping HF, metabolic, and atherosclerotic risk
Results Cholelithiasis significantly associates GLP1-RAs (p = 0.033)
K.K : Methodology, Formal analysis, Writing Review & Editing